Logo image of CDMO

AVID BIOSERVICES INC (CDMO) Stock Fundamental Analysis

NASDAQ:CDMO - Nasdaq - US05368M1062 - Common Stock - Currency: USD

12.49  +0.01 (+0.08%)

Fundamental Rating

2

Taking everything into account, CDMO scores 2 out of 10 in our fundamental rating. CDMO was compared to 551 industry peers in the Biotechnology industry. Both the profitability and financial health of CDMO have multiple concerns. CDMO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CDMO had negative earnings in the past year.
CDMO had a positive operating cash flow in the past year.
In multiple years CDMO reported negative net income over the last 5 years.
CDMO had a positive operating cash flow in 4 of the past 5 years.
CDMO Yearly Net Income VS EBIT VS OCF VS FCFCDMO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

The Return On Assets of CDMO (-47.00%) is comparable to the rest of the industry.
CDMO has a worse Return On Equity (-339.34%) than 76.46% of its industry peers.
Industry RankSector Rank
ROA -47%
ROE -339.34%
ROIC N/A
ROA(3y)-3.99%
ROA(5y)-4.97%
ROE(3y)-52.56%
ROE(5y)-37.94%
ROIC(3y)N/A
ROIC(5y)N/A
CDMO Yearly ROA, ROE, ROICCDMO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

1.3 Margins

Looking at the Gross Margin, with a value of 7.68%, CDMO is in the better half of the industry, outperforming 73.81% of the companies in the same industry.
In the last couple of years the Gross Margin of CDMO has declined.
The Profit Margin and Operating Margin are not available for CDMO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 7.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-44.47%
GM growth 5Y-17.19%
CDMO Yearly Profit, Operating, Gross MarginsCDMO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

More info and screens

1

2. Health

2.1 Basic Checks

CDMO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CDMO has been increased compared to 1 year ago.
The number of shares outstanding for CDMO has been increased compared to 5 years ago.
The debt/assets ratio for CDMO is higher compared to a year ago.
CDMO Yearly Shares OutstandingCDMO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CDMO Yearly Total Debt VS Total AssetsCDMO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -0.51, we must say that CDMO is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.51, CDMO is in the better half of the industry, outperforming 61.95% of the companies in the same industry.
CDMO has a Debt/Equity ratio of 3.58. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of CDMO (3.58) is worse than 84.07% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.58
Debt/FCF N/A
Altman-Z -0.51
ROIC/WACCN/A
WACC8.72%
CDMO Yearly LT Debt VS Equity VS FCFCDMO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 1.30 indicates that CDMO should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.30, CDMO is doing worse than 83.89% of the companies in the same industry.
CDMO has a Quick Ratio of 1.30. This is a bad value and indicates that CDMO is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.92, CDMO is doing worse than 87.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 0.92
CDMO Yearly Current Assets VS Current LiabilitesCDMO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

6

3. Growth

3.1 Past

CDMO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1305.88%.
Looking at the last year, CDMO shows a very negative growth in Revenue. The Revenue has decreased by -15.80% in the last year.
CDMO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.15% yearly.
EPS 1Y (TTM)-1305.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
Revenue 1Y (TTM)-15.8%
Revenue growth 3Y13.42%
Revenue growth 5Y21.15%
Sales Q2Q%31.84%

3.2 Future

Based on estimates for the next years, CDMO will show a very strong growth in Earnings Per Share. The EPS will grow by 27.71% on average per year.
Based on estimates for the next years, CDMO will show a very strong growth in Revenue. The Revenue will grow by 22.14% on average per year.
EPS Next Y86.15%
EPS Next 2Y38.79%
EPS Next 3Y27.71%
EPS Next 5YN/A
Revenue Next Year17.28%
Revenue Next 2Y17.02%
Revenue Next 3Y18.3%
Revenue Next 5Y22.14%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
CDMO Yearly Revenue VS EstimatesCDMO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
CDMO Yearly EPS VS EstimatesCDMO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CDMO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CDMO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDMO Price Earnings VS Forward Price EarningsCDMO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDMO Per share dataCDMO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

CDMO's earnings are expected to grow with 27.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.79%
EPS Next 3Y27.71%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CDMO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVID BIOSERVICES INC

NASDAQ:CDMO (2/4/2025, 8:00:02 PM)

12.49

+0.01 (+0.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-10 2024-12-10/amc
Earnings (Next)04-22 2025-04-22/amc
Inst Owners105.25%
Inst Owner Change-14.63%
Ins Owners0.95%
Ins Owner Change0%
Market Cap801.11M
Analysts74.55
Price Target12.75 (2.08%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-92.85%
Min EPS beat(2)-125.28%
Max EPS beat(2)-60.43%
EPS beat(4)0
Avg EPS beat(4)-1306.42%
Min EPS beat(4)-4971.9%
Max EPS beat(4)-60.43%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.13%
Min Revenue beat(2)-3.38%
Max Revenue beat(2)-2.89%
Revenue beat(4)0
Avg Revenue beat(4)-1.8%
Min Revenue beat(4)-3.38%
Max Revenue beat(4)-0.02%
Revenue beat(8)3
Avg Revenue beat(8)-3.35%
Revenue beat(12)7
Avg Revenue beat(12)0.75%
Revenue beat(16)11
Avg Revenue beat(16)3.84%
PT rev (1m)0%
PT rev (3m)-7.41%
EPS NQ rev (1m)-9.09%
EPS NQ rev (3m)-50%
EPS NY rev (1m)-1.69%
EPS NY rev (3m)-1.69%
Revenue NQ rev (1m)-2.16%
Revenue NQ rev (3m)0.42%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)-0.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.32
P/FCF N/A
P/OCF 152.36
P/B 17.88
P/tB 17.88
EV/EBITDA N/A
EPS(TTM)-2.39
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)0.08
OCFY0.66%
SpS2.35
BVpS0.7
TBVpS0.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47%
ROE -339.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 7.68%
FCFM N/A
ROA(3y)-3.99%
ROA(5y)-4.97%
ROE(3y)-52.56%
ROE(5y)-37.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-44.47%
GM growth 5Y-17.19%
F-Score4
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 3.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 119.78%
Cap/Sales 9.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.3
Quick Ratio 0.92
Altman-Z -0.51
F-Score4
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)874.1%
Cap/Depr(5y)606.28%
Cap/Sales(3y)40.63%
Cap/Sales(5y)27.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1305.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
EPS Next Y86.15%
EPS Next 2Y38.79%
EPS Next 3Y27.71%
EPS Next 5YN/A
Revenue 1Y (TTM)-15.8%
Revenue growth 3Y13.42%
Revenue growth 5Y21.15%
Sales Q2Q%31.84%
Revenue Next Year17.28%
Revenue Next 2Y17.02%
Revenue Next 3Y18.3%
Revenue Next 5Y22.14%
EBIT growth 1Y-69.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year176.36%
EBIT Next 3Y71.06%
EBIT Next 5YN/A
FCF growth 1Y89.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y277.64%
OCF growth 3Y-29.44%
OCF growth 5YN/A